News und Analysen
VISIOMED GROUP : Succès de la présentation de VisioCheck(R), la première station de télémédecine mobile et connectée au monde de moins de 300 grammes, au Salon des Maires et des Collectivités Locales
Paris, le 24 octobre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, a présenté VisioCheck®, son dispositif ultra-portable....
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
After FDA commissioner Scott Gottlieb issued a statement suggesting an easier path to winning approval for generic opioids that are abuse deterrent, shares in Collegium Pharmaceutical's (NASDAQ:....
Mazor Robotics Might Need to Worry About This Potential Rival the Most (Hint: It's Not Intuitive Surgical)
When it comes to the use of robots in spine surgery, Mazor Robotics (NASDAQ: MZOR) clearly has the early-mover advantage. The Israel-based company claims more than 170 surgical robot systems....
Medicrea annonce l'homologation par la FDA de ses dispositifs intersomatiques en titane imprimés en 3D
Medicrea annonce l'homologation par la FDA de ses dispositifs intersomatiques en titane, imprimés en 3D, et présente AdapTEK, sa gamme adaptative d'implants de fusion.
Lyon et New York, 22....
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
Why OraSure Technologies, Inc. Zoomed Higher Today
OraSure Technologies (NASDAQ: OSUR) is up 18.6% at 3:42 p.m. EST Tuesday after the company announced that it entered into a $143 million agreement to supply its Oragene devices to an undisclosed....
Agilent Technologies (A) Q4 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Agilent Technologies (NYSE: A) Q4 2017 Earnings Conference CallNov. 20, 2017 4:30 p.m. ETOperatorContinue readingSource: Fool.com
NxStage Medical Prepares for Fresenius Merger
NxStage Medical (NASDAQ: NXTM) is in an awkward position right now, and it's one that any investor in a company that has received an acquisition bid can understand. The maker of home dialysis....
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
At a recent healthcare conference, Gilead Sciences (NASDAQ: GILD) CEO John Milligan laid out his top three priorities for 2018. Here's what he said (this and all other quotes courtesy of S&P....
Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each....
Will UnitedHealth Group Do a Stock Split in 2018?
Healthcare remains in flux, with changing policies concerning the Affordable Care Act and health insurance more broadly having a huge impact on the industry. As a leader in the health insurance....
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
5 Lesser-Known Rule Breakers: Where We Stand at the 2-Year Mark
On this week's Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviews the performance of a set of his stock picks made up of companies most folks won't have heard of.Based on....
3 Biotech Stocks to Be Thankful for This Year
Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it's....
Ending Obamacare's Individual Mandate Would All but Kill an Already Compromised Law
The winds of change are in the air in Washington, and it has absolutely nothing to do with turkey dinners and pumpkin-spiced lattes. The long-awaited tax reform from Republicans, the current....
The Medicare Mistake That Could Cost 62% of Senior Enrollees a Fortune in 2018
For many retired Americans, Social Security is probably the most important social program. It's not hard to imagine why, either. It provides a guaranteed monthly stipend for more than three out of....
3 Biotech Stocks That Soared: Are They Buys?
Some of the biggest moves week in and week out come from biotech stocks. Whether it's a financial surprise, a positive clinical-trial update, regulatory approval, or even just rumors of....
What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses....
Is Loxo Oncology's Deal With Bayer Bad News?
After reporting that global biopharma giant Bayer AG (NASDAQOTH: BAYRY) has inked a licensing deal for its most advanced clinical-stage drug, shares in Loxo Oncology (NASDAQ: LOXO) tumbled. Is....
3 Top Medical Device Stocks to Buy Now
Healthcare investors tend to focus all of their attention on biotechnology or pharmaceutical stocks. That's a shame, because the medical device industry has some wonderful traits that make it a....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
3 Reasons Novavax Stock Could Double in 2018
Charles Dickens' introduction to A Tale of Two Cities sort of applies to Novavax's (NASDAQ: NVAX) experience in 2017 so far: "It was the best of times, it was the worst of times..."At two....
Why Vascular Biogenics Ltd. Is Tanking Today
After the company released the pricing details of its just-announced common stock offering, shares of Vascular Biogenics (NASDAQ: VBLT), a clinical-stage biotech focused on cancer, fell 18% as of....
Medigene: Unter 10 EUR? Ist doch super!
Die Anteile des Biotechnologieunternehmens Medigene zeigen in diesem Jahr riesige Kursausschläge. Von 30 bis 70 Prozent nach oben und von 30 bis 45 Prozent nach unten ist fast alles dabei. Allein....
